Patients with atypical hemolytic uremic syndromes (HUS) have genetic mutations in the alternate complement pathway and a high rate of recurrence post renal transplantation. Renal transplantation in this group of patients carries a high risk of graft failure and mortality. Eculizumab has been used as a prophylactic measure, but is expensive, frequently inaccessible and has no definite recommendations for cessation of use.
No takes yet. Share an insight, caveat, or question.
Ganesh et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: